US$ 24.29
glp-1 shortage GLP-1s Going Direct, How Novo and Lilly's DTC Strategy is Changing the Game for Patients and Plan Sponsors The GLP-1 receptor agonist shortage:
Description
Obesity and insulin resistance

Wegovy: In trials of the 25 mg pill, participants lost an average of 13.6% of body weight over 71 weeks, compared to just over 2% in the placebo group

Wegovy savings offer

These activities are carried out by specialty clinics, retail and online pharmacies, pharma patient-support divisions, digital health partners, and patient advocacy groups
